In these nerve-muscle connections from frog embryos, the highest level of calcium that builds up near the release site determines how much neurotransmitter is released, regardless of how quickly or how long the calcium entered.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether peak [Ca²⁺]AZ is the dominant regulator of neurotransmitter release across diverse vertebrate synapses, integrating findings from multiple in vivo and in vitro models.
A systematic review and meta-analysis of all peer-reviewed studies measuring [Ca²⁺]AZ and neurotransmitter release in vertebrate synapses (including mammalian CNS, frog NMJ, and rodent neuromuscular junctions), using standardized methods for calcium imaging and release quantification, with subgroup analysis by synapse maturity and calcium channel type.
Whether experimentally manipulating peak [Ca²⁺]AZ (via controlled calcium influx protocols) directly causes proportional changes in neurotransmitter release, independent of other variables.
A double-blind, randomized experiment in intact Xenopus neuromuscular junctions using optogenetic calcium uncaging to precisely control peak [Ca²⁺]AZ (e.g., 20 μM vs. 50 μM) while holding influx duration and rate constant, measuring quantal release via postsynaptic current amplitude in 50+ preparations, with blinding to calcium concentration.
Whether naturally occurring variations in peak [Ca²⁺]AZ predict differences in synaptic strength across developing Xenopus neuromuscular junctions over time.
A longitudinal cohort study tracking 100+ Xenopus nerve-muscle synapses from embryonic stage to maturity, measuring peak [Ca²⁺]AZ (via BK current kinetics) and EPSC amplitude weekly, controlling for age, temperature, and muscle activity, to determine if peak [Ca²⁺]AZ predicts synaptic maturation rate.
Whether synapses with consistently lower peak [Ca²⁺]AZ are associated with reduced neurotransmitter release in genetically modified Xenopus models.
A case-control study comparing 30 Xenopus embryos with CRISPR-mediated knockdown of L-type calcium channels (cases) to 30 wild-type controls, measuring peak [Ca²⁺]AZ and EPSC amplitude at identical developmental stages, with blinding to genotype.
Whether a correlation exists between peak [Ca²⁺]AZ and EPSC amplitude across a population of Xenopus varicosity synapses at a single developmental time point.
A cross-sectional measurement of [Ca²⁺]AZ (via BK current kinetics) and EPSC amplitude in 150+ Xenopus nerve-muscle varicosities at day 3 post-culture, with standardized voltage protocols and blinding to measurement order.